Literature DB >> 8554944

The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers.

J Roberts1, D G Waller, N O'Shea, B S Macklin, A G Renwick.   

Abstract

The plasma pharmacokinetics of levodopa were studied in eight healthy young subjects following an i.v. infusion of 50 mg over 5 min. Subjects were studied on two occasions in random order following treatment with carbidopa; on one occasion they were pretreated with selegiline (four doses of 10 mg over the preceding 3 days) and on the other with a placebo. The mean plasma concentration-time curves on each occasion were essentially superimposable and there were no significant differences in any calculated pharmacokinetic parameter. Selegiline does not significantly alter the distribution or elimination of levodopa from plasma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8554944      PMCID: PMC1365161          DOI: 10.1111/j.1365-2125.1995.tb04564.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease.

Authors:  J M Cedarbaum; M Silvestri; M Clark; A Harts; H Kutt
Journal:  Clin Neuropharmacol       Date:  1990-02       Impact factor: 1.592

2.  The influence of levodopa on gastric emptying in man.

Authors:  D R Robertson; A G Renwick; N D Wood; N Cross; B S Macklin; J S Fleming; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

3.  The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.

Authors:  D R Robertson; N D Wood; H Everest; K Monks; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

4.  Variability of L-dopa absorption in man.

Authors:  D N Wade; P T Mearrick; D J Birkett; J Morris
Journal:  Aust N Z J Med       Date:  1974-04

Review 5.  On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics.

Authors:  J G Nutt
Journal:  Ann Neurol       Date:  1987-10       Impact factor: 10.422

6.  Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain.

Authors:  T B Nguyen; M Angers
Journal:  Biochem Pharmacol       Date:  1987-05-15       Impact factor: 5.858

7.  Changes in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration.

Authors:  K Baraczka; M I Fekete; B Kanyicska
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

8.  Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment.

Authors:  E H Heinonen; U K Rinne; J Tuominen
Journal:  Acta Neurol Scand Suppl       Date:  1989

9.  Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging.

Authors:  F Baronti; T L Davis; R C Boldry; M M Mouradian; T N Chase
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

10.  Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.

Authors:  M Takahashi; R Yuasa; T Imai; H Tachibana; S Yorifuji; Y Nakamura; N Ogawa
Journal:  Intern Med       Date:  1994-09       Impact factor: 1.271

View more
  3 in total

1.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 2.  The Human Experience with Intravenous Levodopa.

Authors:  Shan H Siddiqi; Natalia K Abraham; Christopher L Geiger; Morvarid Karimi; Joel S Perlmutter; Kevin J Black
Journal:  Front Pharmacol       Date:  2016-01-06       Impact factor: 5.810

Review 3.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.